Chordomas are rare, slow-growing neoplasms, characterized by locally aggressive growth patterns and high local recurrence rates. To the best of our knowledge, the MGMT promoter methylation status has not been studied in a population of patients with chordomas to determine if a biologic rationale exists to support the use of temozolomide. We here show for the first time that methylation of MGMT promoter is present in a significant portion or recurring clival chordomas; on the contrary in clival chordomas without recurrence MGMT promoter was always unmethylated (p = 0.0317). Although these observations need to be confirmed in a larger study population, our results (1) indicate that methylation of MGMT promoter is present in a significant portion of recurring chordomas, and (2) prompt further investigation into the potential role of temozolomide as an adjuvant treatment of these tumors. © 2014 Springer Science+Business Media New York.

Marucci, G., Morandi, L., Mazzatenta, D., Frank, G., Pasquini, E., Foschini, M.P. (2014). MGMT promoter methylation status in clival chordoma. JOURNAL OF NEURO-ONCOLOGY, 118(2), 271-276 [10.1007/s11060-014-1445-y].

MGMT promoter methylation status in clival chordoma

MARUCCI, GIANLUCA;MORANDI, LUCA;MAZZATENTA, DIEGO;FRANK, GIORGIO;PASQUINI, ERNESTO;FOSCHINI, MARIA PIA
2014

Abstract

Chordomas are rare, slow-growing neoplasms, characterized by locally aggressive growth patterns and high local recurrence rates. To the best of our knowledge, the MGMT promoter methylation status has not been studied in a population of patients with chordomas to determine if a biologic rationale exists to support the use of temozolomide. We here show for the first time that methylation of MGMT promoter is present in a significant portion or recurring clival chordomas; on the contrary in clival chordomas without recurrence MGMT promoter was always unmethylated (p = 0.0317). Although these observations need to be confirmed in a larger study population, our results (1) indicate that methylation of MGMT promoter is present in a significant portion of recurring chordomas, and (2) prompt further investigation into the potential role of temozolomide as an adjuvant treatment of these tumors. © 2014 Springer Science+Business Media New York.
2014
Marucci, G., Morandi, L., Mazzatenta, D., Frank, G., Pasquini, E., Foschini, M.P. (2014). MGMT promoter methylation status in clival chordoma. JOURNAL OF NEURO-ONCOLOGY, 118(2), 271-276 [10.1007/s11060-014-1445-y].
Marucci, Gianluca; Morandi, Luca; Mazzatenta, Diego; Frank, Giorgio; Pasquini, Ernesto; Foschini, MARIA PIA
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/566605
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 17
social impact